
ChromaDex Corp (NAGE) Stock Forecast & Price Target
ChromaDex Corp (NAGE) Analyst Ratings
Bulls say
Niagen Bioscience is a unique company in the health and wellness space, with a strong focus on NAD+ science and a robust portfolio of over 100 patents. The company's flagship product, Tru Niagen, has been clinically proven to increase NAD+ levels and has potential for broad use in both the supplement and pharmaceutical markets. Additionally, the company's recent expansion into the skincare market and its plans to introduce a pen-like autoinjector and other innovative products highlight its strong potential for growth. While risks such as slower sales growth and potential legal issues exist, the company's recent lawsuit against regulators could provide a long-term tailwind. With a solid financial standing, including strong projected cash on hand and moderate revenue outperformance, Niagen Bioscience has the potential for continued success in the rapidly growing health and wellness market.
Bears say
Niagen Bioscience is a leader in the NAD+ science and healthy-aging industry, but they face challenges in maintaining sales growth and financial stability. The company's reliance on their Tru Niagen brand and ongoing lawsuits and negative studies in regards to their products could hurt their reputation and sales. Furthermore, the highly competitive nature of the health and wellness market, potential regulatory changes, and stock dilution risk could also negatively impact the company's financial outlook.
This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.
ChromaDex Corp (NAGE) Analyst Forecast & Price Prediction
Start investing in ChromaDex Corp (NAGE)
Order type
Buy in
Order amount
Est. shares
0 shares